Roche’s Crenezumab Creeps Forward But Has All To Play For In Phase III Trials

Phase II data for Roche’s Alzheimer’s disease MAb, crenezumab, has upheld its proposed mechanism of action but competitor aducanumab still has the upper hand with evidence of disease-modifying potential.